Our collaborators and partners are driven by a desire to contribute to the development of new ways of fighting cancer. The therapies developed by NETRIS Pharma are based on cellular mechanisms identified by a world-renowned research group.
Located in Léon Bérard Cancer Center (Lyon, France), NETRIS Pharma is a unique model of a biotechnology company integrated within a comprehensive cancer center.
NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – has been invited by the French Embassy of Luxembourg in order to present NETRIS Pharma research…
NETRIS Pharma announces that ANR (Agence Nationale de la Recherche) granted the translational RHU TROY program aiming at Targeting dependence Receptors (DRs) in Oncology and hematologY. This program aims at…
NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – was nominated as “Chevalier de la Légion d’Honneur”, following the recommendation of Najat Vallaud-Belkacem, French Minister…
NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – received the 2015 Irène Joliot-Curie award from the French Minister of Education and Research and the…
NETRIS Pharma will attend the BioEquity Europe 2015 meeting in Vienna, Austria (May 19th-20th). During the “Next Wave Companies” session, Stéphane Depil – CEO – will present NETRIS Pharma activities…
NETRIS Pharma will attend the AACR Annual Meeting 2015 in Philadelphia, US (April 18th-22nd). For this occasion, NETRIS Pharma will present recent data regarding its first-in-class humanized anti-Netrin-1 antibody NP137,…
NETRIS Pharma will attend the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. For this occasion, NETRIS Pharma will present the preclinical characteristics of NP137, its...
NETRIS Pharma - a Lyon-based biotech firm aiming at translating the dependence receptor paradigm to the clinic - presents today its new website. This website introduces company missions, objectives, business...
